Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Agreement to Supply Adderall XR(R) Authorized Generic

2nd Dec 2013 12:00

SHIRE PLC - Agreement to Supply Adderall XR(R) Authorized Generic

SHIRE PLC - Agreement to Supply Adderall XR(R) Authorized Generic

PR Newswire

London, December 2

Shire Enters Into Agreement to Supply Adderall XR® Authorized Generic Philadelphia, PA, United States - December 2, 2013 - Shire plc (LSE: SHP,NASDAQ: SHPG), announces that its subsidiary Shire US Inc. has entered into anagreement to supply an authorized generic version of its product Adderall XR.Under the agreement, Sandoz Inc. will market an authorized generic version ofAdderall XR® beginning July 1, 2016. From the December 1, 2013 effective dateof the agreement through the end of the agreement's five-year term, Sandoz hasagreed to exclusively sell the authorized generic version of Adderall XRsupplied by Shire. Shire will manufacture and supply Sandoz with all dosage strengths of theauthorized generic product. Sandoz will distribute the product in the UnitedStates. Shire will receive a royalty from Sandoz's sales of the product. For further information please contact: Investor Relations Eric Rojas erojas@shire.com +1 781 482 0999 Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157 Media Jessica Mann jmann@shire.com +44 1256 894 280 Gwen Fisher gfisher@shire.com +1 484 595 9836 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,Internal Medicine and Regenerative Medicine and we are developing treatmentsfor symptomatic conditions treated by specialist physicians in other targetedtherapeutic areas. www.shire.com FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATESECURITIES LITIGATION REFORM ACT OF 1995 Statements included in this announcement that are not historical facts areforward-looking statements. Forward-looking statements involve a number ofrisks and uncertainties and are subject to change at any time. In the eventsuch risks or uncertainties materialize, Shire's results could be materiallyadversely affected. The risks and uncertainties include, but are not limitedto, that: * Shire's products may not be a commercial success; * revenues from ADDERALL XR are subject to generic erosion; * the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues and earnings; * Shire relies on a single source for manufacture of certain of its products and a disruption to the supply chain for those products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis; * Shire uses third party manufacturers to manufacture many of its products and is reliant upon third party contractors for certain goods and services, and any inability of these third party manufacturers to manufacture products, or any failure of these third party contractors to provide these goods and services, in each case in accordance with its respective contractual obligations, could adversely affect Shire's ability to manage its manufacturing processes or to operate its business; * the development, approval and manufacturing of Shire's products is subject to extensive oversight by various regulatory agencies and regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches; * the actions of certain customers could affect Shire 's ability to sell or market products profitably and fluctuations in buying or distribution patterns by such customers could adversely impact Shire's revenues, financial conditions or results of operations; * investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines; * adverse outcomes in legal matters and other disputes, including Shire's ability to obtain, maintain, enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations; and other risks and uncertainties detailed from time to time in Shire's filingswith the U.S. Securities and Exchange Commission, including its most recentAnnual Report on Form 10-K. Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com

Related Shares:

Shire
FTSE 100 Latest
Value8,941.12
Change-34.54